9krapalm.com

WuXi AppTec Achieved First Quarter 2024 Target Despite External Challenges, Maintaining Stable Operations

SHANGHAI, April 29, 2024 /PRNewswire/ — WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and life sciences industry, today announced its financial results for the first quarter ending March 31, 2024 (“Reporting Period”): 

[1] In 2023 Q1 and 2024 Q1, WuXi AppTec had a fully-diluted weighted average share count of 2,948,890,231 and 2,925,052,346 ordinary shares, respectively.

Management Comment

Dr. Ge Li, Chairman and CEO of WuXi AppTec, said, “We achieved our targets for the first quarter of 2024. For the full year, the Company expects to deliver revenue of RMB 38.3-40.5 billion and free cash flow of RMB 4-5 billion, while adjusted non-IFRS NPM is expected to remain at a similar level as last year.”

“Since its founding in 2000, WuXi AppTec has dedicated itself to serving as a highly efficient enabler to the industry, creating value for our customers and benefiting patients globally. Over the past two decades, the Company has remained fully committed to the highest quality and compliance standards, prioritizing our customers’ needs, protecting their intellectual property (IP), and abiding by the laws and regulations in the countries in which we operate. Thanks to the trust and support from our customers globally, the Company continues to support the industry and enable our customers with continuously enhanced capabilities and capacity. With constantly emerging scientific innovations, including the rapid development of artificial intelligence (AI), the industry’s demand for CRO, CDMO, CRDMO and CTDMO services will continue to grow – and this is the inevitable trend of the industry. Although the recently proposed U.S. legislation may create short-term uncertainty for the Company, our customers and the global pharmaceutical and life sciences industry, WuXi AppTec remains steadfast in ‘doing the right thing and doing it right’ and in supporting our customers’ efforts to bring groundbreaking therapies to patients around the world.”

Business Performance by Segments

[2] To further strengthen the CRDMO business integration, business units have been adjusted accordingly, and so have the R and D&M revenue splits (similar to 2023 baseline).

[3] WuXi DDSU will not be shown separately in the subsequent earnings presentation, as its revenue currently accounts for only ~1% of the Company.

This release provides a summary of the results and is not intended to be a comprehensive report. For additional information, please refer to the WuXi AppTec 2024 First Quarterly Results Presentation and 2024 First Quarterly Report disclosed on the Company’s official website, as well as the 2024 First Quarterly Report and other relevant announcements published on the websites of the Shanghai Stock Exchange (www.sse.com.cn) and the Stock Exchange of Hong Kong (www.hkexnews.hk), and the designated media for dissemination of the relevant information. Investors are advised to exercise caution and be aware of the investment risks in trading Company shares.

All financial information disclosed in this press release is prepared based on International Financial Reporting Standards (IFRS), in currency of RMB.

The 2024 First Quarterly Report of the Company has not been audited.

First Quarter 2024 Results by Segments

Unit: RMB million

Segment

Revenue

Change

Adjusted non-
IFRS Gross Profit

Change

Adjusted non-
IFRS Gross Profit Margin

WuXi
Chemistry

5,562.63

(13.5) %

2,409.05

(16.6) %

43.3 %

WuXi Testing

1,490.61

2.6 %

531.11

0.6 %

35.6 %

WuXi Biology

560.81

(2.8) %

215.84

(9.9) %

38.5 %

WuXi ATU

280.27

(13.6) %

(91.96)

Note1

(32.8) %

WuXi DDSU

80.08

(51.8) %

21.57

(46.0) %

26.9 %

Others

7.54

(29.0) %

4.14

(37.0) %

54.9 %

Total

7,981.93

(11.0) %

3,089.74

(16.0) %

38.7 %

Notes: 1. Adjusted non-IFRS gross profit of WuXi ATU was RMB(91.96) million in Q1 2024,
compared to RMB(24.01) million in Q1 2023, a decline of RMB67.95 million.

2. Any sum of the data above that is inconsistent with the total is due to rounding.

 

Consolidated Statement of Profit or Loss[4] – Prepared under IFRS

RMB Million

First quarter of
2024

First quarter of
2023

Year-over-
Year

Change

Revenue

7,981.9

8,963.7

(11.0) %

Cost of services

(4,976.2)

(5,438.1)

(8.5) %

Gross profit

3,005.7

3,525.6

(14.7) %

Other income

242.0

196.0

23.5 %

Other gains and losses

192.9

197.8

(2.5) %

Impairment losses under expected credit
  losses (“ECL”) model, net of reversal

(19.7)

(6.3)

213.2 %

Selling and marketing expenses  

(179.1)

(175.9)

1.8 %

Administrative expenses 

(610.5)

(669.4)

(8.8) %

Research and development expenses

(306.4)

(357.3)

(14.2) %

Operating Profit

2,324.9

2,710.5

(14.2) %

Share of results of associates

33.9

(45.8)

(174.1) %

Share of results of joint ventures

0.2

8.3

(97.5) %

Finance costs

(61.7)

(64.2)

(3.9) %

Profit before tax

2,297.4

2,608.9

(11.9) %

Income tax expense

(338.5)

(423.1)

(20.0) %

Profit for the period

1,958.9

2,185.8

(10.4) %

Profit for the period attributable to:

Owners of the Company

1,942.2

2,168.1

(10.4) %

Non-controlling interests

16.6

17.7

(5.8) %

1,958.9

2,185.8

(10.4) %

Weighted average number of ordinary shares
for calculating EPS(express in shares)

– Basic

2,919,696,373

2,933,625,180

(0.5) %

– Diluted

2,925,052,346

2,948,890,231

(0.8) %

Earnings per share attributable to ordinary
shareholders of the Company (expressed in
RMB per share)

– Basic

0.67

0.74

(9.5) %

– Diluted

0.66

0.72

(8.3) %

[4] If the sum of the data below is inconsistent with the total, it is caused by rounding

 

 

 

Consolidated Statement of Financial Position[5]– Prepared under IFRS

RMB Million

March 31,

December 31,

2024

2023

Non-current Assets

Property, plant and equipment

26,045.5

25,844.4

Rightofuse assets

2,313.6

2,348.3

Goodwill

1,834.7

1,820.9

Other intangible assets

883.4

906.7

Interests in associates

2,260.3

2,180.4

Interests in joint ventures

36.0

35.2

Deferred tax assets

506.0

366.7

Financial assets at fair value through profit or
  loss (“FVTPL”)

8,742.1

8,626.0

Other non-current assets

114.2

105.8

Biological assets

1,050.6

1,012.5

43,786.5

43,246.9

Current Assets

Inventories

3,148.5

2,886.1

Contract costs

784.3

695.6

Biological assets

1,115.2

1,154.6

Amounts due from related parties

95.3

86.7

Trade and other receivables

8,524.5

9,372.7

Contract assets

1,249.5

1,234.4

Income tax recoverable

7.4

17.5

Financial assets at FVTPL

503.1

11.0

Derivative financial instruments

0.0

414.0

Other current assets

785.8

Pledged bank deposits

1.6

1.6

Term deposits with initial term of over three
  months

4,207.0

3,761.4

Bank balances and cash

11,517.0

10,001.0

31,153.4

30,422.5

Total Assets

74,939.8

73,669.3

[5] If the sum of the data below is inconsistent with the total, it is caused by rounding.

 

 

 

Consolidated Statement of Financial Position (continued)[6]– Prepared under IFRS

RMB Million

March 31,

December 31,

2024

2023

Current Liabilities

Trade and other payables

6,487.5

7,333.5

Amounts due to related parties

7.3

11.5

Derivative financial instruments

793.5

501.9

Contract liabilities

2,162.5

1,955.4

Bank borrowings

2,939.2

3,721.6

Lease liabilities

232.7

240.5

Income tax payables

764.8

991.9

13,387.4

14,756.3

Non-current Liabilities

Bank borrowings

2,863.0

687.0

Deferred tax liabilities

516.7

530.1

Deferred income

1,064.9

1,079.9

Lease liabilities

1,059.4

1,098.6

5,504.1

3,395.6

Total Liabilities

18,891.6

18,151.9

Net Assets

56,048.3

55,517.4

Capital and Reserves

Share capital 

2,933.3

2,968.8

Reserves

52,706.2

52,153.6

Equity attributable to the owners of the
 Company

55,639.5

55,122.5

Non-controlling interests

408.8

395.0

Total Equity

56,048.3

55,517.4

[6] If the sum of the data below is inconsistent with the total, it is caused by rounding.

 

 

 

Adjusted Non-IFRS Net Profit Attributable to the Owners of the Company[7]

RMB Million

First quarter of
2024

First quarter of
2023

Year-over-Year

Change

Net Profit Attributable to the Owners of the
  Company under IFRS

1,942.2

2,168.1

(10.4) %

Add:

Share-based compensation expenses

87.8

166.3

(47.2) %

                 Issuance expenses of convertible bonds

0.3

N/A

                 Fair value gains from derivative
                    component of convertible bonds

(40.2)

N/A

                 Foreign exchange related losses

14.4

164.2

(91.2) %

                 Amortization of acquired intangible
                    assets from merge and acquisition

13.6

14.1

(3.5) %

Non-IFRS Net Profit attributable to the
  owners of the Company

2,058.0

2,472.8

(16.8) %

Add:

Realized and unrealized gains from
   venture capital investments

(144.7)

(122.4)

18.2 %

Realized and unrealized share of gains
   from joint ventures

(0.2)

(8.3)

(97.6) %

Adjusted non-IFRS net profit attributable to
  the owners of the Company

1,913.1

2,342.1

(18.3) %

[7] If the sum of the data below is inconsistent with the total, it is caused by rounding.

 

About WuXi AppTec

As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, advanced therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the third consecutive year in 2023 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that “every drug can be made and every disease can be treated.” Please visit: http://www.wuxiapptec.com

Forward-Looking Statements

This press release may contain certain “forward-looking statements” which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, the ability of our service offerings to compete effectively, our ability to meet timelines for the expansion of our service offerings, our ability to protect our customers’ intellectual property, unforeseeable international tension, competition, the impact of emergencies and other force majeure. Our forward-looking statements in this press release speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by applicable law or listing rules. Accordingly, you are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section. All information provided in this press release is as of the date of this press release and are based on assumptions that we believe to be reasonable as of this date, and we do not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Use of Non-IFRS and Adjusted Non-IFRS Financial Measures

We provide non-IFRS gross profit and non-IFRS net profit attributable to the owners of the Company, which exclude share-based compensation expenses, issuance expenses of convertible bonds, fair value gain or loss from derivative component of convertible bonds, foreign exchange-related gains or losses, amortization of intangible assets acquired in business combinations, non-financial assets impairment, talent incentive and retention expenses funded by cash donation from shareholders, etc. We also provide adjusted non-IFRS net profit attributable to the owners of the Company and earnings per share, which further exclude realized and unrealized gains or losses from our venture capital investments and joint ventures. Neither is required by, or presented in accordance with IFRS.

We believe that the adjusted financial measures used in this press release are useful for understanding and assessing our core business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual, non-recurring, non-cash and non-operating items that we do not consider indicative of the performance of our core business. Such adjusted non-IFRS net profit attributable to the owners of the Company, the management of the Company believes, is widely accepted and adopted in the industry the Company is operating in. However, the presentation of these adjusted non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with IFRS. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRS, or as being comparable to results reported or forecasted by other companies.

 

View original content to download multimedia: Read More

Exit mobile version